1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
621B7370EB2473E82002587300034C70A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-leveraging-outcomes-data-launch-investment-technology-health-economics-outcomes-research-cns-products?opendocument
18
19opendocument
203.237.16.210
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Health Outcomes

Leveraging Outcomes Data – Launch Investment and Technology in Health Economics & Outcomes Research for CNS Products

ID: 5691


Features:

6 Info Graphics

7 Data Graphics

140+ Metrics

1 Narratives


Pages/Slides: 21


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Leveraging Outcomes Data – Launch Investment and Technology in Health Economics & Outcomes Research for CNS Products”

STUDY OVERVIEW

Demonstrating a CNS product’s value proposition and its potential in real-world practice is integral to maximizing clinical and market success.

The Health Economics Outcomes Research function is a key player in generating value-oriented outcomes data, but organizations need to invest in HEOR activities at the right time in the development process and use the right technology platforms to effectively communicate outcomes data to internal and external stakeholders.

Best Practices, LLC conducted this benchmarking research to illustrate investment timing for HEOR activities and effective technology applications for presenting health outcomes data to key internal and external stakeholders.

Study insights are further segmented based on the HEOR reporting structure.

KEY TOPICS

  • Launch investment for HEOR activities
  • Effective technologies for health outcomes data communication
  • Tools used to demonstrate value

KEY METRICS
  • At which point investment begins and at which point maximum investment is reached in different HEOR activities to develop value assessments for new therapies?
  • How effective are the listed technologies to enable field communication tools?
  • How often technologies are updated?
  • What tools are used by HEOR groups to showcase value/ communicate with payers?

SAMPLE KEY FINDINGS
  • Launch Investment: Early-stage lifecycle investments (<Phase III) build competitive advantage to maximize ROI and optimize commercial success.

METHODOLOGY

Best Practices, LLC engaged 16 executives from 14 pharmaceuticals offering CNS products. The study insights are mostly from directors and higher management executives, representing around ninety percent of the participants. Functional segments in the study will help pinpoint differences in value delivery among Medical Affairs and Commercial HEOR groups.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Communications


Companies Profiled:
AbbVie; Alexion Pharmaceuticals; Bayer; Brii Biosciences; CSL Behring; Eisai; Greenwich Biosciences; Harmony Biosciences; Lundbeck; Merck; Novartis; Nucleus Global; Pfizer; Takeda Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.